Fosaprepitant

For research use only. Not for therapeutic Use.

  • CAT Number: I002246
  • CAS Number: 172673-20-0
  • Molecular Formula: C₂₃H₂₂F₇N₄O₆P
  • Molecular Weight: 614.41
  • Purity: ≥95%
Inquiry Now

Fosaprepitant (Cat.No:I002246) is a prodrug of aprepitant, an antiemetic medication used to prevent and treat chemotherapy-induced nausea and vomiting. Fosaprepitant is administered intravenously and is rapidly converted to aprepitant in the body. It works by blocking the action of substance P, a neurotransmitter involved in the vomiting reflex.


Catalog Number I002246
CAS Number 172673-20-0
Synonyms

[5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-3-oxo-1H-1,2,4-triazol-2-yl]phosphonic acid

Molecular Formula C₂₃H₂₂F₇N₄O₆P
Purity ≥95%
Target Substance P/NK1 Receptor
Solubility 10 mM in DMSO
Storage Store at -20℃
IUPAC Name [3-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-5-oxo-4H-1,2,4-triazol-1-yl]phosphonic acid
InChI InChI=1S/C23H22F7N4O6P/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)40-20-19(13-2-4-17(24)5-3-13)33(6-7-39-20)11-18-31-21(35)34(32-18)41(36,37)38/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H,31,32,35)(H2,36,37,38)/t12-,19+,20-/m1/s1
InChIKey BARDROPHSZEBKC-OITMNORJSA-N
SMILES CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NC(=O)N(N3)P(=O)(O)O)C4=CC=C(C=C4)F
Reference

<p style=/line-height:25px/>
<br>[1]. Navari RM. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2008 Nov;8(11):1733-42.
<br>[2]. Olver IN. Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant. Ther Clin Risk Manag. 2008 Apr;4(2):501-6.
<br>[3]. Grunberg S, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol–EASE. J Clin Oncol. 2011 Apr 10;29(11):1495-501.
<br>[4]. Saito H, et al. Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Ann Oncol. 2013 Apr;24(4):1067-73.
</p>

Request a Quote